Figure 4
PD901 and PTT combine to decrease MPNST progression and increase survival in vivo.
MPNST-bearing B6129SF1/J mice were treated once tumors reached 10 mm in diameter with: no treatment (n = 5, black), 5 mg/kg PD901 (n = 5, blue), PTT (n = 5, red; 1.0 mg/mL PBNPs with 1.5 W/cm2), or PD901 + PTT (n = 5, purple; both PD901 and PTT treatments). PD901 was administered by oral gavage daily. PBNPs were administered intratumorally and PTT was performed once for ten minutes. Animals were euthanized when tumors reached 20 mm in diameter or showed signs of distress. (a) Tumor progression was measured every day by calipers. Each line represents one mouse. Insets: Tumors were harvested 8 h post-treatment, processed for histology, stained with H&E, and visualized by microscopy; scale bar = 20 μm. (b) Survival is illustrated by a Kaplan-Meier curve. *p < 0.05 compared to all groups by log-rank test.
